docetaxel anhydrous has been researched along with Pancreatic Neoplasms in 133 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 13 (9.77) | 18.2507 |
2000's | 63 (47.37) | 29.6817 |
2010's | 51 (38.35) | 24.3611 |
2020's | 6 (4.51) | 2.80 |
Authors | Studies |
---|---|
Chen, Y; Guo, W; He, Y; Krimm, I; Li, Y; Liu, M; Mi, D; Pei, H; Shao, T; Wang, P; Wang, X; Yi, Z; Zhang, Y | 1 |
Deva, S; Findlay, M; Hitchen, N; Lawrence, B; Waldron, NR | 1 |
Asahina, S; Choi, G; Choi, SJ; Choy, JH; Jin, GW; Lee, HJ; Piao, H; Rejinold, NS | 1 |
Hao, L; Hu, H; Li, N; Li, Z; Qi, G; Shi, G; Wang, S; Yin, Q; Zhang, Z | 1 |
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
Bengrine, L; Fumet, JD; Ghiringhelli, F; Granconato, L; Hennequin, A; Palmier, R; Vincent, J | 1 |
Bu, LP; Li, XY; Liu, H; Liu, P; Shao, L; Ying, Q; Yu, SQ | 1 |
Cai, W; Duan, Y; Li, Q; Shen, J; Yang, H; Yao, K; Zhao, P; Zhao, Z; Zhou, Y | 1 |
Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
Chen, W; Feng, J; Huang, X; Liu, P; Shao, L; Sun, M; Sun, Q; Xiao, R; Xiong, J; Xiong, M; Yu, X; Yuan, W; Zhang, Q; Zhao, X | 1 |
Almawash, SA; Mahato, RI; Mondal, G | 1 |
Alseidi, A; Badiozamani, K; Biehl, TR; Edwards, AM; Helton, WS; Kanji, ZS; Kozarek, RA; Lin, BS; Mandelson, MT; Picozzi, VJ; Rocha, FG; Sahar, N; Song, G | 1 |
Egger, J; Hann, A; Hermann, PC; Keller, F; Nosalski, E; Seufferlein, T | 1 |
Hajatdoost, L; Kosari, S; Sedaghat, K; Thomas, J; Walker, EJ | 1 |
Tian, Q; Wang, Y; Zhang, F | 1 |
Awasthi, N; Hinz, S; Schwarz, AM; Schwarz, MA; Schwarz, RE; Wang, C; Williams, NS; Zhang, C | 1 |
Goodman, MD; Huber, K; McPartland, S; Saif, MW | 1 |
Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
Ichioka, D; Kawai, K; Kimura, T; Miyazaki, J; Nagata, C; Nagumo, Y; Nishiyama, H; Oikawa, T; Suetomi, T; Uchida, M | 1 |
Ajouz, H; Elias, E; Faraj, W; Haydar, A; Khalife, M; Mukherji, D; Saleh, A; Shamseddine, A; Temraz, S; Yakan, AS | 1 |
Bayraktar, S; Blaya, M; Green, MR; Levi, J; Lopes, G; Macintyre, J; Mayo, C; Merchan, J; Rocha-Lima, CM; Silva, O; Soares, HP; Walker, G | 1 |
Benson, AB; Berlin, J; Burtness, B; Catalano, P; Chapman, AE; Liles, DK; Mitchell, E; Powell, M | 1 |
Barth, RJ; Colacchio, TA; Gardner, TB; Gordon, SR; Hessami, N; Klibansky, DA; Mody, K; Pipas, JM; Putra, J; Ripple, GH; Smith, KD; Suriawinata, AA; Tsapakos, MJ; Tsongalis, GJ; Zaki, B | 1 |
Abbas, M; Adenis, A; Baey, C; Bennouna, J; Boige, V; Cellier, P; Conroy, T; Ducreux, M; Giovannini, M; Juzyna, B; Llacer, C; Mornex, F; Peiffert, D; Pignon, JP; Viret, F | 1 |
Psyrri, A; Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
Kaddis, N; Saif, MW | 1 |
Addeo, G; Allendorf, J; Chabot, J; Chu, K; Fine, RL; Hecht, E; Jin, B; Leung, D; Postolov, I; Remotti, H; Schrope, BA; Sherman, WH; Tsai, W | 1 |
Gao, Z; Jiang, C; Jin, M; Li, P; Li, Y | 1 |
Cho, M; Fournier, C; Gao, F; Linehan, D; Myerson, R; Nagaraj, G; Parikh, P; Picus, J; Sorscher, S; Strasberg, S; Suresh, R; Tan, BR; Wang-Gillam, A | 1 |
Cao, P; Do, T; Ernsting, MJ; Gill, B; Hedley, D; Hoang, B; Li, SD; Lohse, I; Pintilie, M; Undzys, E | 1 |
Guillen, KP; Harrison, RG; Kurkjian, C; Restuccia, A | 1 |
Ikuta, S; Inoue, K; Sonoda, T; Tani, S; Tsubamoto, H; Yamanaka, N | 1 |
Armstrong, PA; Centeno, BA; Chen, DT; Fulp, WJ; Gamenthaler, AW; Ha, TT; Hodul, PJ; Hoffe, S; Hutchinson, T; Illig, K; Johnson, BL; Malafa, MP; Nguyen, P; Pimiento, JM; Rashid, OM; Shridhar, R; Springett, G | 1 |
Balaji, U; Conway, W; Eslinger, C; Knudsen, ES; McMillan, E; Mills, GB; O'Reilly, EM; Posner, B; Witkiewicz, AK | 1 |
Choi, EK; Chung, HK; Jeong, SY; Jung, J; Jung, KH; Kim, KP; Lee, JS; Lee, SW; Park, J; Seo, MH; Song, SY | 1 |
Cereda, S; Reni, M | 1 |
Beer, TM; Blanke, CD; Lopez, C; Mori, M; Stone, M; Todd, K | 1 |
Gennatas, C; Gennatas, S; Michalaki, V | 1 |
Berglund, A; Byström, P; Frödin, JE; Glimelius, B; Johansson, B; Letocha, H; Nygren, P; Pedersen, D | 1 |
Brell, JM; Dranko, S; Evans, T; Kiefer, GJ; Lenzner, D; Matin, K; Ramanathan, RK; Rath, L; Schlesselman, JJ; Schmotzer, A; Volkin, RL | 1 |
Carvajal, RD; Gilman-Rosen, L; Gonen, M; Kelsen, DP; Kortmansky, J; Lefkowitz, RA; O'Reilly, EM; Schwartz, GK; Shah, MA; Tse, A | 1 |
Alpaugh, K; Borghaei, H; Cohen, RB; Dueland, S; Forsberg, G; Hawkins, R; Hedlund, G; Langer, C; Lassen, U; Rogatko, A | 1 |
Fridley, BL; Jenkins, GD; Kalari, KR; Li, L; Lingle, W; Lou, Z; Pei, H; Petersen, G; Wang, L | 1 |
Halldén, G | 1 |
Bender, GP; Masellis, AM; Sielaff, TD | 1 |
Cusnir, M; Enzinger, PC; Goldberg, RM; Gorsch, SM; Hollis, DR; Kindler, HL; Kulke, MH; Mayer, RJ; Niedzwiecki, D; Tempero, MA | 1 |
Alemany, R; Cascallo, M; Fillat, C; Gros, A; Martinez-Quintanilla, J | 1 |
Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J | 1 |
Bozionelou, V; Georgoulias, V; Giassas, S; Kalbakis, K; Katopodis, O; Kentepozidis, N; Mavroudis, D; Polyzos, A; Rovithi, M; Vamvakas, L | 1 |
Bekaii-Saab, T; Bloomston, M; Campbell, A; Culler, K; Hejna, G; Hill, ME; Kim, S; Li, X; Zalupski, M | 1 |
Amadori, D; Arienti, C; Carloni, S; Chiadini, E; Fabbri, F; Leonetti, C; Milandri, C; Orlandi, A; Passeri, D; Scarsella, M; Silvestrini, R; Tesei, A; Ulivi, P; Zoli, W; Zupi, G | 1 |
Kaley, K; Penney, R; Saif, MW; Syrigos, K | 1 |
Azria, D; Delpero, JR; Giovannini, M; Moureau-Zabotto, L; Moutardier, V; Rouanet, P; Turrini, O; Viret, F; Ychou, M | 1 |
Gordian, E; Miller, H; Ramachandran, K; Rocha-Lima, C; Singal, R | 1 |
Awasthi, N; Schwarz, MA; Schwarz, RE | 1 |
Fujiwara, H; Ichikawa, D; Iitaka, D; Ikoma, H; Kawaguchi, T; Kokuba, Y; Komatsu, S; Konishi, H; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Sonoyama, T; Yoshikawa, T | 1 |
Awasthi, N; Brekken, RA; Kirane, A; Schwarz, MA; Schwarz, RE; Toombs, JE | 1 |
Centeno, B; Helm, J; Hodul, P; Hoffe, S; Kim, J; Klapman, J; Malafa, M; Patel, M; Springett, G; Valone, T | 1 |
Gnant, M; Goetzinger, P; Koelblinger, C; Kuehrer, I; Sahora, K; Schindl, M | 1 |
Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E | 1 |
Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L | 1 |
Abbruzzese, JL; Carlson, PJ; Dakik, HK; Fogelman, DR; Moskovic, DJ; Qiao, W; Tamm, EP; Wolff, RA | 1 |
Adenis, A; Baey, C; Bennouna, J; Berille, J; Celier, P; Ducreux, M; Mornex, F; Oberic, L; Peiffert, D; Pignon, JP; Viret, F; Ychou, M | 1 |
Cantore, M; Cereda, S; Funel, N; Ghidini, M; Giovannetti, E; Leon, LG; Lucchesi, M; Mambrini, A; Pacetti, P; Peters, GJ; Reni, M; Vasile, E | 1 |
Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH | 1 |
Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M | 1 |
Kang, J; Li, A; Wang, Z; Wu, X; Yang, J; Zeng, Y | 1 |
Belli, C; Cereda, S; Reni, M | 1 |
Jacobs, AD | 1 |
Asaumi, Y; Hara, T; Hirano, M; Kikkawa, H; Kikuchi, T; Murakami, N; Nozawa, H; Takizawa, M; Uno, Y | 1 |
André, T; Artru, P; Louvet, C | 1 |
André, T; Culine, S; Epaud, C; Gligorov, J | 1 |
Abbruzzese, JL | 1 |
Heinemann, V | 4 |
Katano, M; Matsunaga, H; Morisaki, T; Nagumo, F; Nakahara, C; Sato, N; Tadano, J; Zhang, H | 1 |
Haller, DG | 1 |
Bories, E; Braud, AC; Camerlo, J; Dubois, JB; Genre, D; Giovannini, M; Gonçalves, A; Gravis, G; Magnin, V; Maraninchi, D; Moutardier, V; Viens, P; Viret, F; Ychou, M | 1 |
Calley, C; Fata, F; Ganjoo, KN; Loehrer, PJ; Picus, J; Schneider, BP; Seitz, DE; Stoner, C | 1 |
McConkey, DJ; Nawrocki, ST; Sweeney-Gotsch, B; Takamori, R | 1 |
Ali, S; El-Rayes, BF; Ellis, KL; Kucuk, O; Li, Y; Nedeljkovic-Kurepa, A; Philip, PA; Sarkar, FH | 1 |
Aviles, V; Benson, AB; Berlin, JD; Harris, JE; Levy, DE; Shepard, RC; Stuart, K; Thomas, JP | 1 |
Clarke, PA; Evans, SA; Gilliam, AD; Grabowska, AM; Harris, JC; McKenzie, AJ; McWilliams, DF; Watson, SA | 1 |
Aboulafia, DM; Jacobs, AD; Otero, H; Picozzi, VJ | 1 |
Bonetto, E; Di Carlo, V; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Ronzoni, M; Staudacher, C; Villa, E; Zerbi, A | 1 |
Hribaschek, A; Lippert, H; Lueck, A; Meyer, F; Ridwelski, K | 1 |
Chin, K; Hatake, K; Inamura, K; Ito, Y; Kobayashi, T; Mishima, Y; Mizunuma, N; Nagasaki, E; Nishimori, H; Shinozaki, E; Takahashi, S; Terui, Y; Yokoyama, M | 1 |
Lutz, MP | 1 |
Lopes, G; Rocha Lima, CM | 1 |
Ahmed, F; Ali, S; Kucuk, O; Li, Y; Philip, PA; Sarkar, FH | 1 |
Büchler, MW; Büchler, P; Eibl, G; Friess, H; Hines, OJ; Isacoff, WH; Reber, HA; Roth, MA | 1 |
Barth, RJ; Bettmann, MA; Cates, JM; Colacchio, TA; Cole, BF; Gordon, SR; Marshall, JF; McDonnell, CE; Meyer, LP; Perez, RP; Pipas, JM; Redfield, N; Ripple, GH; Suriawinata, AA; Sutton, JE; Tsapakos, MJ; Zaki, B | 1 |
Burdick, RK; Cunningham, SC; Cusnir, M; Moesinger, R; Van Echo, DA | 1 |
Arnaud, JP; Debois, M; Ducreux, MP; El-Serafi, M; Etienne, PL; Gamelin, E; Genicot, B; Husseini, F; Koehne, CH; Lingenfelser, T; Lutz, MP; Mitry, E; Nordlinger, B; Praet, M; Reichardt, P; Van Cutsem, E; Van Laethem, JL; Vanhoefer, U; Wagener, T; Wils, JA | 1 |
Fahlke, J; Florschuetz, A; Greiner, C; Hahnfeld, S; Hribaschek, A; Kettner, E; Klein, H; Kuhn, R; Lippert, H; Manger, T; Meyer, F; Ridwelski, K; Wilhelm, G | 1 |
Boku, N; Fukutomi, A | 1 |
Desai, K; Einstein, M; Fields, A; Goel, S; Goldberg, G; Macapinlac, M; Mani, S; Martin, R; Volterra, F; Wadler, S; Wong, B | 1 |
Attarpour, M; Balcer-Kubiczek, EK; Jiang, J; Kennedy, AS; Suntharalingam, M | 1 |
Delpero, JR; Turrini, O | 1 |
Geng, M; Ji, YB; Jiang, JS; Li, H; Lou, GY; Ma, T; Xi, WQ; Xia, HQ; YeE, ZB | 1 |
Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H | 1 |
Andrade, R; Chabot, J; Desai, M; Fine, RL; Fogelman, DR; Guba, S; Schreibman, SM; Sherman, W; Strauss, J | 1 |
Amarantidis, K; Chatzaki, E; Houhouli, K; Kakolyris, S; Lyrantzopoulos, N; Matthaios, D; Miloussis, A; Papatheodorou, K; Tentes, A; Tsaroucha, A | 1 |
Chan, A; Chan, F; Chen, R; Cusatis, G; Garrett-Mayer, E; Hallur, G; Hamel, E; Hidalgo, M; Jimeno, A; Khan, S; Shah, P; Zhang, X | 1 |
Christophylakis, C; Georgoulias, V; Ignatiadis, M; Kalbakis, K; Kotsakis, A; Polyzos, A; Potamianou, A; Stathopoulos, GP; Tselepatiotis, E; Vamvakas, L | 1 |
Abou-Alfa, GK; O'Reilly, EM | 1 |
Bergsland, EK; Dito, E; Ko, AH; Schillinger, B; Tempero, MA; Venook, AP | 1 |
Taguchi, T | 1 |
Macdonald, JS; Schnall, SF | 1 |
Rougier, P | 1 |
Trudeau, ME | 1 |
Sakata, Y; Suzuki, H; Takemori, H | 1 |
Bissery, MC; Fellous, A; Martinez, C; Veitia, R | 1 |
Orel, NF | 1 |
Kurihara, M; Matsuno, S; Ohashi, Y; Okada, S; Sakata, Y; Sasaki, Y; Taguchi, T | 1 |
Choy, H | 1 |
Androulakis, N; Aravantinos, G; Dimopoulos, MA; Genatas, K; Georgoulias, V; Kakolyris, S; Karabekios, S; Kourousis, C; Papadimitriou, C; Samelis, G; Stathopoulos, GP; Tsavaris, N | 1 |
Cascinu, S; Catalano, G; Catalano, V; Gasparini, G; Gattuso, D; Giordani, P; Morabito, A; Pancera, G; Silva, RR | 1 |
Cascinu, S; Graziano, F | 1 |
Adenis, A; Armand, JP; Baille, P; Blanc, C; Bonneterre, J; Clouet, P; de Forni, M; Dembak, M; Ducreux, M; Lebecq, A; Lefresne-Soulas, F; Rougier, P | 1 |
Barbier, P; Bissery, MC; David, S; Fellous, A; Gounon, P; Vantard, M; Veitia, R | 1 |
Agelaki, S; Aravantinos, G; Georgoulias, V; Kakolyris, S; Karabekios, S; Kouroussis, C; Mavroudis, D; Rigatos, SK; Stathopoulos, GP; Tsavaris, N | 1 |
Fine, RL; Sherman, WH | 1 |
Appert, HE; Howard, JM; Iwamura, T; Liu, B; Staren, ED | 1 |
Clark, JW; Earle, CC; Fuchs, CS; Grossbard, ML; Grossman, SR; Kim, H; Kulke, MH; Mayer, RJ; Morgan, JA; Ryan, DP; Shivdasani, R | 1 |
Appert, H; Howard, J; Iwamura, T; Liu, B; Staren, E | 2 |
Bruckner, HW; Kozuch, P; Petryk, M | 1 |
Abbruzzese, JL; Evans, DB; Lenzi, R; Yalcin, S | 1 |
Bissery, MC; Guénard, D; Guéritte-Voegelein, F; Lavelle, F | 1 |
24 review(s) available for docetaxel anhydrous and Pancreatic Neoplasms
Article | Year |
---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kidney Failure, Chronic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Renal Dialysis; Taxoids | 2018 |
Chemotherapy in Pancreatic Cancer: A Systematic Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2018 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Male; Mitoxantrone; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Taxoids; Virus Replication | 2009 |
In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Docetaxel; Drug Interactions; Humans; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Taxoids | 2010 |
Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2002 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Pancreatic Neoplasms; Signal Transduction; Taxoids; Transcription Factors; Treatment Failure | 2002 |
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
New perspectives in the management of pancreas cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Taxoids | 2003 |
Docetaxel in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids; Thalidomide | 2005 |
[Activity of Taxanes for advanced and recurrent pancreatic cancer].
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2006 |
Cytotoxic therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids | 2007 |
Chemotherapy of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Growth Substances; Humans; Immunologic Factors; Octreotide; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate; Taxoids | 1996 |
Docetaxel delivers new management opportunities for gastrointestinal carcinomas.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Docetaxel; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids | 1995 |
Docetaxel: a review of its pharmacology and clinical activity.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Eruptions; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Microtubules; Neutropenia; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Taxoids; Tubulin | 1996 |
[Chemotherapy for pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Irinotecan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Taxoids | 1996 |
[Taxotere in various solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 1998 |
Taxanes in combined-modality therapy for solid tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids | 1999 |
Gemcitabine: progress in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Matrix Metalloproteinase Inhibitors; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Gemcitabine-based combination treatment of pancreatic cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Patient Selection; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome | 2002 |
Present and future treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2002 |
44 trial(s) available for docetaxel anhydrous and Pancreatic Neoplasms
Article | Year |
---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Clinical assessment of palliative radiotherapy for pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiosurgery; Surveys and Questionnaires; Treatment Outcome | 2018 |
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2014 |
Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cetuximab; Diarrhea; Disease-Free Survival; Docetaxel; Enoxaparin; Female; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Response Evaluation Criteria in Solid Tumors; Survival Rate; Taxoids; Thromboembolism | 2016 |
Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2014 |
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Taxoids; Treatment Outcome | 2015 |
A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Polymeric nanoparticle-docetaxel for the treatment of advanced solid tumors: phase I clinical trial and preclinical data from an orthotopic pancreatic cancer model.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Male; Maximum Tolerated Dose; Mice; Middle Aged; Nanoparticles; Neoplasm Staging; Neoplasms; Pancreatic Neoplasms; Polymers; Taxoids; Treatment Outcome; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Calcitriol; Calcium Channel Agonists; Calcium, Dietary; Disease Progression; Docetaxel; Drug Therapy, Combination; Fatigue; Female; Humans; Hyperglycemia; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2009 |
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Digestive System Neoplasms; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Stomach Neoplasms; Taxoids; Treatment Outcome; Vitamin B Complex | 2010 |
Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Taxoids | 2009 |
A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Flavonoids; Humans; Male; Middle Aged; Pancreatic Neoplasms; Piperidines; Taxoids; Treatment Outcome | 2009 |
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cytokines; Docetaxel; Enterotoxins; Europe; Female; Humans; Immunoconjugates; Kidney Neoplasms; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Pancreatic Neoplasms; Recombinant Fusion Proteins; Taxoids; Time Factors; Treatment Outcome; United States | 2009 |
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Confidence Intervals; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome; United States | 2009 |
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Leukopenia; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Surveys and Questionnaires; Survival Rate; Taxoids; Treatment Outcome | 2011 |
A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival; Taxoids | 2011 |
Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Confidence Intervals; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Taxoids | 2011 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Taxoids; Treatment Outcome | 2011 |
Docetaxel and radiotherapy and pancreatic cancer.
Topics: Adenocarcinoma; Aged; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Taxoids; Time Factors | 2003 |
Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate; Taxoids; Time Factors | 2003 |
Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Failure; United States | 2004 |
Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids | 2004 |
Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Pancreatic Neoplasms; Salvage Therapy; Taxoids; Treatment Outcome | 2004 |
Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Health Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain Measurement; Pancreatic Neoplasms; Quality of Life; Severity of Illness Index; Taxoids | 2004 |
Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Conformal; Taxoids | 2005 |
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2005 |
Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Ribonucleotide Reductases; Survival Rate; Taxoids; Treatment Outcome | 2006 |
A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Oligonucleotides; Pancreatic Neoplasms; Prothrombin Time; Taxoids | 2006 |
[Locally advanced pancreatic adenocarcinoma. Chemoradiotherapy, reevaluation and secondary resection].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Humans; Length of Stay; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Dosage; Survival Analysis; Taxoids | 2006 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Patient Compliance; Stomach Neoplasms; Taxoids; Treatment Outcome | 2006 |
A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Taxoids | 2006 |
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Taxoids | 2008 |
[An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Colonic Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids | 1994 |
Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Taxoids | 1999 |
Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Patient Compliance; Survival Rate; Taxoids; Treatment Outcome | 1999 |
A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Severity of Illness Index; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 1999 |
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Docetaxel; Female; France; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Taxoids; Treatment Outcome | 2001 |
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2002 |
Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Dexamethasone; Diphenhydramine; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2002 |
66 other study(ies) available for docetaxel anhydrous and Pancreatic Neoplasms
Article | Year |
---|---|
Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin.
Topics: Animals; Antineoplastic Agents; Calcium-Binding Proteins; Cell Line, Tumor; Cell Movement; Drug Design; Epithelial-Mesenchymal Transition; Humans; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Muscle Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Structure-Activity Relationship; Triazoles; Xenograft Model Antitumor Assays | 2019 |
Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Febrile Neutropenia; Gemcitabine; Humans; Middle Aged; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2023 |
NOAEL cancer therapy: a tumor targetable docetaxel-inorganic polymer nanohybrid prevents drug-induced neutropenia.
Topics: Docetaxel; Humans; Neutropenia; No-Observed-Adverse-Effect Level; Pancreatic Neoplasms; Polymers; Taxoids | 2023 |
cRGD-Conjugated GdIO Nanoclusters for the Theranostics of Pancreatic Cancer through the Combination of T
Topics: Docetaxel; Gadolinium; Humans; Iron; Magnetic Resonance Imaging; Pancreatic Neoplasms; Precision Medicine; Tumor Microenvironment | 2023 |
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Curcumin enhances anti‑cancer efficacy of either gemcitabine or docetaxel on pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadherins; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Curcuma; Curcumin; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pancreatic Neoplasms; Plant Extracts; Poly (ADP-Ribose) Polymerase-1; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2020 |
Preparation of multifunctional nanobubbles and their application in bimodal imaging and targeted combination therapy of early pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Contrast Media; Docetaxel; Drug Delivery Systems; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Particle Size; Photochemotherapy; Photothermal Therapy; Tissue Distribution; Treatment Outcome; Tumor Burden; Ultrasonography; Xenograft Model Antitumor Assays | 2021 |
Synergistic effects of baicalein with gemcitabine or docetaxel on the proliferation, migration and apoptosis of pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Synergism; Flavanones; Gemcitabine; Humans; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Taxoids | 2017 |
Coadministration of Polymeric Conjugates of Docetaxel and Cyclopamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Drug Liberation; Hedgehogs; Humans; Mice; Micelles; Microtubules; Neoplasm Metastasis; Pancreatic Neoplasms; Polymers; Proton Magnetic Resonance Spectroscopy; Taxoids; Veratrum Alkaloids | 2018 |
Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Survival Rate | 2018 |
Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Docetaxel; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Neoplasms, Experimental; Paclitaxel; Pancreatic Neoplasms; Stathmin; Stromal Cells; Taxoids; Tubulin; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
New developments in the management of borderline resectable pancreatic cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Caproates; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Taxoids; Treatment Outcome | 2013 |
New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Docetaxel; Erlotinib Hydrochloride; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Taxoids; Treatment Outcome | 2013 |
[Long-term survival with gemcitabine and docetaxel for renal leiomyosarcoma : a case report].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kidney Neoplasms; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Pancreatic Neoplasms; Taxoids | 2013 |
Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2014 |
The effect of neoadjuvant chemoradiation on pancreatic cancer-associated diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy; Deoxycytidine; Diabetes Mellitus; Docetaxel; Fasting; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Paraneoplastic Syndromes; Retrospective Studies; Single-Blind Method; Taxoids; Treatment Outcome; Tumor Burden | 2014 |
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Taxoids; Treatment Outcome | 2014 |
Second-line treatment for pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Metformin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Docetaxel-encapsulating small-sized polymeric micelles with higher permeability and its efficacy on the orthotopic transplantation model of pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Compounding; Female; Humans; Mice; Micelles; Pancreatic Neoplasms; Permeability; Polymers; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle.
Topics: Animals; Antineoplastic Agents; Carboxymethylcellulose Sodium; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Female; Fibroblasts; Humans; Mice; Mice, Inbred C57BL; Nanoparticles; Neoplasm Metastasis; Pancreas; Pancreatic Neoplasms; Polyethylene Glycols; Taxoids; Xenograft Model Antitumor Assays | 2015 |
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
Topics: Adenine; Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur Lyases; Cell Death; Cell Line, Tumor; Cytosine Deaminase; Docetaxel; Dose-Response Relationship, Drug; Enzymes; Flucytosine; Fluorouracil; Humans; Methanol; Molecular Targeted Therapy; Organoselenium Compounds; Pancreatic Neoplasms; Prodrugs; Purine-Nucleoside Phosphorylase; Recombinant Fusion Proteins; Selenomethionine; Taxoids; Tubulin Modulators; Vidarabine | 2015 |
Combination Chemotherapy with Itraconazole for Treating Metastatic Pancreatic Cancer in the Second-line or Additional Setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Itraconazole; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Taxoids | 2015 |
Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Critical Pathways; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiosurgery; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Dasatinib; Docetaxel; Drug Resistance, Neoplasm; Everolimus; Exome; Humans; Mice; Models, Genetic; Models, Statistical; Pancreatic Neoplasms; Precision Medicine; Prognosis; Pyridones; Pyrimidinones; Taxoids; Xenograft Model Antitumor Assays | 2016 |
Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Salvage Therapy; Taxoids | 2008 |
FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line; Cell Line, Tumor; Cytarabine; Docetaxel; Drug Therapy; Humans; Kidney; Neoplasms; Nuclear Proteins; Paclitaxel; Pancreatic Neoplasms; Phosphoprotein Phosphatases; Proto-Oncogene Proteins c-akt; Tacrolimus Binding Proteins; Taxoids | 2009 |
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Ganciclovir; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Humans; Male; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Taxoids; Thymidine Kinase; Transfection; Xenograft Model Antitumor Assays | 2009 |
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Quinazolines; Retrospective Studies; Salvage Therapy; Taxoids | 2010 |
Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; CARD Signaling Adaptor Proteins; Cell Line, Tumor; Cytoskeletal Proteins; Deoxycytidine; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Silencing; Humans; Pancreatic Neoplasms; Promoter Regions, Genetic; Taxoids; Transfection | 2010 |
Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Proliferation; Cell Survival; Cytokines; Docetaxel; Doxorubicin; Drug Synergism; Flow Cytometry; Humans; Immunohistochemistry; Mice; Mice, SCID; Neoplasm Proteins; Pancreatic Neoplasms; RNA-Binding Proteins; Survival Analysis; Taxoids; Tetrazolium Salts; Xenograft Model Antitumor Assays | 2011 |
[A case report--locally advanced pancreatic adenocarcinoma was resected after chemotherapy].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Duodenal Neoplasms; Humans; Male; Mesenteric Artery, Superior; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Taxoids; Tegafur | 2010 |
Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Biomimetic Materials; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Gemcitabine; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Mice; Mice, SCID; Mitochondrial Proteins; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Survival Analysis; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids | 2011 |
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Thrombocytopenia; Treatment Failure | 2012 |
Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; DNA Repair; DNA Repair Enzymes; Docetaxel; Drug Resistance, Neoplasm; Female; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Prognosis; Taxoids; Xeroderma Pigmentosum Group D Protein | 2011 |
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Length of Stay; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quinazolines; Survival Rate; Taxoids | 2012 |
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
[Enhanced proliferation inhibition and apoptosis-inducing effects of docetaxel-loaded lipid microbubble on human pancreatic cancer cells in vitro].
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Carriers; Humans; Microbubbles; Pancreatic Neoplasms; Taxoids | 2012 |
Role of taxanes in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Radiotherapy; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
[A case of recurrent gastric cancer that responded dramatically to docetaxel and 5'-DFUR combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Floxuridine; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome | 2002 |
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2002 |
PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1.
Topics: Apoptosis; Cell Division; Docetaxel; Humans; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Proteoglycans; Taxoids; Tumor Cells, Cultured | 2003 |
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Division; Cell Line, Tumor; Docetaxel; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitosis; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Protease Inhibitors; Pyrazines; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Synergism; Drug Therapy, Combination; Genistein; Humans; NF-kappa B; Pancreatic Neoplasms; Taxoids | 2004 |
The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA, Antisense; Docetaxel; Gastrins; Gemcitabine; Gene Expression; Genetic Therapy; Humans; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Precursors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Taxoids; Transfection | 2004 |
[An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2005 |
[Chemotherapy of pancreatic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2005 |
Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Docetaxel; Doxorubicin; Drug Synergism; Genistein; Humans; Lung Neoplasms; Male; Neoplasms; NF-kappa B; Pancreatic Neoplasms; Prostatic Neoplasms; Taxoids | 2005 |
Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy.
Topics: Agar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Recombinant Proteins; Taxoids; Time Factors; Trastuzumab | 2005 |
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Cytotoxicity of docetaxel (Taxotere) used as a single agent and in combination with radiation in human gastric, cervical and pancreatic cancer cells.
Topics: Cell Nucleus; Cell Survival; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Humans; Microscopy, Fluorescence; Mitotic Index; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids; Tumor Cells, Cultured; Uterine Cervical Neoplasms; X-Rays | 2006 |
[In vitro chemo-sensitivity MTT assay guided intraperitoneal chemotherapy for malignant ascites].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ascites; Camptothecin; Cell Survival; Colorectal Neoplasms; Docetaxel; Female; Humans; Injections, Intraperitoneal; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids; Tumor Cells, Cultured | 2006 |
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Taxoids; Vascular Neoplasms | 2006 |
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Mice; Mice, Nude; Microtubules; Neoplasm Transplantation; Pancreatic Neoplasms; Phenylurea Compounds; Sulfur; tau Proteins; Taxoids; Tubulin | 2007 |
Docetaxel and gemcitabine released for cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Approval; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids; United States; United States Food and Drug Administration | 1996 |
Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Paclitaxel; Pancreatic Neoplasms; Polymerase Chain Reaction; RNA, Messenger; tau Proteins; Taxoids; Tubulin | 1998 |
Docetaxel chemotherapy for pancreatic cancer: Do results support certainty? Italian Group for the Study of Gastrointestinal Tract Carcinomas.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Granulocyte Colony-Stimulating Factor; Humans; Karnofsky Performance Status; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Reproducibility of Results; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel.
Topics: Amino Acid Sequence; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Blotting, Western; Brain; Carcinoma, Ductal, Breast; Cathepsin D; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Immunohistochemistry; Kinetics; Mice; Mice, Inbred C57BL; Microscopy, Electron; Microtubule-Associated Proteins; Microtubules; Molecular Sequence Data; Paclitaxel; Pancreatic Neoplasms; Peptide Hydrolases; Peptides; Rats; Taxoids; Tubulin; Tumor Cells, Cultured | 2000 |
Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Calcium Channel Blockers; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorescent Dyes; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Paclitaxel; Pancreatic Neoplasms; Rhodamine 123; RNA, Messenger; Taxoids; Tubulin; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Verapamil | 2001 |
Effects of Taxotere on invasive potential and multidrug resistance phenotype in pancreatic carcinoma cell line SUIT-2.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biocompatible Materials; Carcinoma; Collagen; Docetaxel; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorescent Dyes; Humans; In Vitro Techniques; Laminin; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Phenotype; Proteoglycans; Rhodamine 123; RNA, Neoplasm; Taxoids; Tumor Cells, Cultured | 2001 |
Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids; Tumor Cells, Cultured | 2001 |
Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
Topics: Adenocarcinoma; Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Intraductal, Noninfiltrating; Colonic Neoplasms; Docetaxel; Female; Leukemia, Experimental; Lung Neoplasms; Male; Mammary Neoplasms, Experimental; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Neoplasms, Experimental; Osteosarcoma; Paclitaxel; Pancreatic Neoplasms; Sarcoma, Experimental; Taxoids | 1991 |